The sodium–glucose co‐transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor‐β
The results highlight a novel mechanism underlying the beneficial effects of empagliflozin in PAH, through direct binding to the tyrosine kinase effector domain of PDGFRβ. This interaction inhibits PDGFRβ phosphorylation, offering new insights into therapeutic strategies for PAH.
Authors
- Jiang‐Shan Tan (ORCID: https://orcid.org/0000-0001-8154-674X)
- Yan Shu (ORCID: https://orcid.org/0000-0001-8492-1437)
- Tingting Lyu
- Tianqi Li (ORCID: https://orcid.org/0000-0001-7215-2546)
- Jingyang Wang (ORCID: https://orcid.org/0000-0003-4869-696X)
- Yanmin Yang (ORCID: https://orcid.org/0009-0003-2447-7196)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Beijing Anzhen Hospital (CN)
- Heilongjiang Provincial Science and Technology Department (CN)
- Fu Wai Hospital (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1111/bph.70222
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00